{"id":5973,"date":"2025-03-05T16:37:00","date_gmt":"2025-03-05T22:37:00","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5973"},"modified":"2025-09-22T16:39:43","modified_gmt":"2025-09-22T21:39:43","slug":"pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/","title":{"rendered":"Ramesh Arjunji, PhD, ejecutivo farmac\u00e9utico y experto en acceso a terapias gen\u00e9ticas, se une a Nanoscope como vicepresidente ejecutivo de Valor y Acceso"},"content":{"rendered":"
\n
\n
\n
\n
\n

<\/h1>\n<\/div>\n
\n
\n

DALLAS<\/span><\/span>,\u00a05 de marzo de 2025<\/span><\/span> \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraci\u00f3n macular relacionada con la edad (DMRE), anunci\u00f3 hoy que\u00a0Ramesh Arjunji<\/span>, El Dr. Arjunji, doctor en filosof\u00eda, se ha incorporado a Nanoscope como vicepresidente ejecutivo de Valor y Acceso. El Dr. Arjunji aporta una amplia experiencia en comercializaci\u00f3n, I+D, asuntos m\u00e9dicos y desarrollo de negocios, adquirida en diversos puestos de liderazgo en la industria biofarmac\u00e9utica.<\/p>\n

\u201cAdem\u00e1s de su diversa experiencia en la industria, que abarca oftalmolog\u00eda, neurolog\u00eda, oncolog\u00eda, inmunolog\u00eda y dispositivos m\u00e9dicos, Ramesh ha sido un importante l\u00edder en el acceso al mercado para algunas de las terapias g\u00e9nicas comercializadas con mayor \u00e9xito. Esperamos con inter\u00e9s sus contribuciones mientras nos preparamos para lanzar MCO-010 como el primer tratamiento restaurador para pacientes con retinosis pigmentaria\u201d, dijo\u00a0Sulagna Bhattacharya<\/span>, Cofundador y director ejecutivo de Nanoscope.<\/p>\n

\u201cHe tenido el privilegio de guiar el desarrollo y la comercializaci\u00f3n de m\u00faltiples terapias g\u00e9nicas, asegurando que lleguen al mayor n\u00famero posible de pacientes que las necesitan. Me entusiasma poder aprovechar mi experiencia para ayudar a Nanoscope a lograr un \u00e9xito similar y brindar tratamientos que cambien la vida a quienes m\u00e1s los necesitan\u201d, declar\u00f3 el Dr. Arjunji.<\/p>\n

Antes de unirse a Nanoscope, el Dr. Arjunji se desempe\u00f1\u00f3 como Vicepresidente S\u00e9nior de Valor y Acceso Global en Krystal Biotech. Antes de Krystal, fue Vicepresidente y Director de S\u00edntesis de Evidencia en SSI Strategy, donde asesor\u00f3 a clientes sobre estrategias de generaci\u00f3n de evidencia. Antes de SSI Strategy, el Dr. Arjunji fue Vicepresidente de Valor y Acceso en Avrobio, donde lider\u00f3 el desarrollo y la ejecuci\u00f3n de estrategias de generaci\u00f3n de evidencia para productos de terapia g\u00e9nica para trastornos de almacenamiento lisosomal. Antes de Avrobio, el Sr. Arjunji trabaj\u00f3 para AveXis\/Novartis Gene Therapies, donde lider\u00f3 la estrategia y la ejecuci\u00f3n de la participaci\u00f3n global de HTA para ZOLGENSMA, una terapia g\u00e9nica para la atrofia muscular espinal. El Dr. Arjunji tambi\u00e9n ha ocupado puestos de liderazgo en GSK, Alcon, BMS, Biogen, Pfizer, Endo Pharmaceuticals y Centocor\/Johnson & Johnson. Posee un Doctorado en Filosof\u00eda en Ciencias de la Gesti\u00f3n, Marketing y Estad\u00edstica de la Universidad de [Nombre de la universidad].\u00a0Universidad de Texas<\/span>, Maestr\u00eda en Ciencias en Ingenier\u00eda Mec\u00e1nica por\u00a0Universidad Estatal de Florida<\/span>, y Licenciatura en Tecnolog\u00eda Aeron\u00e1utica por la\u00a0Instituto Indio de Tecnolog\u00eda<\/span>.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 no viral administrado por l\u00e1ser listo para IND para GA, as\u00ed como un activo AAV para amaurosis cong\u00e9nita de Leber, en estudios que permiten IND.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0March 5, 2025 \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced that\u00a0Ramesh Arjunji, PhD, has joined Nanoscope as Executive Vice President of Value and Access. Dr. Arjunji brings a breadth of experience including commercialization, R&D, medical affairs and business development gained […]<\/p>\n","protected":false},"author":1,"featured_media":5967,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5973","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nPharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T22:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-22T21:39:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access\",\"datePublished\":\"2025-03-05T22:37:00+00:00\",\"dateModified\":\"2025-09-22T21:39:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/\"},\"wordCount\":495,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_RameshArjunji_V4.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/\",\"name\":\"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_RameshArjunji_V4.jpg\",\"datePublished\":\"2025-03-05T22:37:00+00:00\",\"dateModified\":\"2025-09-22T21:39:43+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_RameshArjunji_V4.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_LI_RameshArjunji_V4.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/03\\\/05\\\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ramesh Arjunji, doctor en filosof\u00eda y ejecutivo farmac\u00e9utico, experto en acceso a la terapia g\u00e9nica, se une a Nanoscope como vicepresidente ejecutivo de Valor y Acceso - Nanoscope Therapeutics.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/","og_locale":"es_MX","og_type":"article","og_title":"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-03-05T22:37:00+00:00","article_modified_time":"2025-09-22T21:39:43+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access","datePublished":"2025-03-05T22:37:00+00:00","dateModified":"2025-09-22T21:39:43+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/"},"wordCount":495,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/","url":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/","name":"Ramesh Arjunji, doctor en filosof\u00eda y ejecutivo farmac\u00e9utico, experto en acceso a la terapia g\u00e9nica, se une a Nanoscope como vicepresidente ejecutivo de Valor y Acceso - Nanoscope Therapeutics.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","datePublished":"2025-03-05T22:37:00+00:00","dateModified":"2025-09-22T21:39:43+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_RameshArjunji_V4.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/03\/05\/pharma-executive-and-gene-therapy-access-expert-ramesh-arjunji-phd-joins-nanoscope-as-executive-vice-president-value-and-access\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5973"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5973\/revisions"}],"predecessor-version":[{"id":9650,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5973\/revisions\/9650"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5967"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}